Fagron Sa Ord (ARSUF) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and good morning, everyone. Welcome to Fagron's Third Quarter 2025 Trading Statement Webcast. I'm joined today by our CEO, Rafael Padilla, and our CFO, Karin De Jong. We will open the floor for questions at the end of the session. And with that, I will hand over to Rafael. Thank you, Matthew, and good morning, all. We're pleased to report a solid quarter where we achieved normalized organic growth of 8.5% and a 5.7% organic growth at CR when including the phase-out of GLP-1s. This quarter, our Wichita facility underwent a routine inspection by the FDA wherein the agency verified the corrective and preventive actions we set in place and received no repeat observations which validates our remediation actions. The FDA also validated the previously announced capacity expansion that is expected to generate $25 million in revenue. We also continued to execute on our M&A strategy as we announced the acquisition of UCP in the U.S., while at the same time we have received competition clearance for Purifarma and Ingeplus in Brazil. In 2025, we have already welcomed eight companies showing our M&A discipline serial acquired profile. And to finalize, we confirm our full year guidance of 930 to 950 million revenue and a slight increase in profitability year on year. Let us now look at the regional dynamics. In Enea, revenue growth was driven by all segments and contributions from our recent acquisitions. V&E saw an impressive quarter as we reap the benefits of our refined commercial strategy, improved operational excellence, and diversified footprint. In compounding services, we benefited from robust demand combined with new customer wins. In Latin America, growth remains solid with all segments contributing positively. Brands' impressive growth trend remains, reflecting th...